Granules India Ltd.
GRANULES · NSE · Healthcare
With a 20% margin of safety, our buy-below price is ₹536.71.
Piotroski F-score 5/9 — quality of earnings & balance sheet.
Investability checklist
- ✕ROE above 15%13.5%
- ✓Low debt (D/E < 0.5)0.30x
- ✓Positive free cash flow
- ✓Revenue growth > 10%23%
- ✓Earnings growing31%
- ✓Net margin ≥ 10%11.1%
- ✓Current ratio > 1.51.80
- ✕Below our fair value
- ✕Margin of safety ≥ 20%
- ✓Above 200-day average
- ✓Above 50-day average
- –Positive 1-year return
- ✓Altman Z in safe zoneZ 5.73
- ✕Piotroski ≥ 75/9
1-year price
EOD · 2026-06-15Our scores
Key fundamentals
SWOT snapshot
Strengths
- •Lightly leveraged balance sheet.
- •Financially solid — Altman Z 5.73.
Opportunities
- •Earnings growing (31% YoY).
- •Revenue growing (23% YoY).
- •Trading in our value buy zone versus sector peers.
About Granules India Ltd.
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions
More in Healthcare
Our verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.